Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

XI Xue

Vascular & Interventional Radiology Las Vegas, NV Medical Doctor

NPI 1700261583 CMS profile 10054713

2020 Palomino Ln Ste 100, Las Vegas, NV 89106

Open in the dashboard

General payments

$7,171

71 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, XI Xue of Las Vegas, NV is reported in the CMS Open Payments database as having received $7,171 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $780 9
2024 General $561 7
2023 General $1,434 15
2022 General $2,800 26
2021 General $1,597 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • XI Xue
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to XI Xue were reported at $780. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year XI Xue Vascular & Interventional Radiology median Middle half National median
2019 $0 $422 $125–$1,555 $163
2020 $0 $200 $68–$652 $114
2021 $1,597 $280 $99–$866 $132
2022 $2,800 $433 $137–$1,497 $149
2023 $1,434 $506 $152–$2,019 $160
2024 $561 $556 $175–$1,930 $164
2025 $780 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Penumbra, Inc. $1,729 14 payments
  2. Inari Medical, Inc. $1,476 12 payments
  3. Boston Scientific Corporation $1,083 12 payments
  4. Sirtex Medical Inc $957 9 payments
  5. Medtronic, Inc. $698 12 payments
  6. Cagent Vascular LLC $293 3 payments
  7. Canon Medical Systems USA, Inc. $263 1 payment
  8. W. L. Gore & Associates, Inc. $216 2 payments
  9. Stryker Corporation $155 2 payments
  10. Viz.Ai, Inc. $147 1 payment
  11. Other $157 3 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,171 71 payments
Products named General payments · program years 2021–2025
  1. FLOWTRIEVER CATHETER, S $1,705 14 payments
  2. CT THROMBECTOMY SYSTEM KIT $1,293 12 payments
  3. Indigo System $1,253 10 payments
  4. SIR-Spheres Microspheres $957 9 payments
  5. TheraSphere Y90 Glass Microspheres 10 GBq $324 2 payments
  6. Serrantor $293 3 payments
  7. INTERVENTIONAL ANGIOGRAPHY SYSTEM $263 1 payment
  8. HawkOne $230 6 payments
  9. KYPHON EXPRESS II KYPHOPAK TRAY $195 2 payments
  10. RED 72 $170 1 payment
  11. Other $1,658 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

31

Median for Diagnostic Radiology: 24

Drug cost

$223

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Metronidazole Generic 16 $137
Ciprofloxacin Hcl Generic 15 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 158 billing codes

Paid by Medicare

$106,578

Of which drugs: $146

Medicare patients

1,519

Average age 74

Services billed

3,527

815 women, 704 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 48%
Ischemic heart disease 47%
Chronic kidney disease 44%
Heart failure 40%
COPD 38%
Atrial fibrillation 35%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 13 1,400 $146

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record